Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Copaxone And Complex Generics: Difficult-To-Copy Does Not Mean Impossible

This article was originally published in RPM Report

Executive Summary

FDA’s approval of the first ANDA for an MS therapy signals the agency’s determination to find a way to get generic versions of complex drugs to market. What if any lessons does that hold for biosimilars?

You may also be interested in...



Pre-ANDA Meeting Goals May Be Created In GDUFA II

Idea could help sponsors of complex generics, but will it extend to other ANDAs?

GDUFA II: Priority Reviews Considered For Some ANDAs

New pathway could restart argument between industry and FDA over what qualifies for expedited review.

Copaxone Generics: FDA Approval Standards Defy Teva’s Argument On Complexity

Sandoz/Momenta’s Glatopa (glatiramer) met four criteria for equivalence that ‘provide overlapping and confirmatory evidence of active ingredient sameness,’ FDA says.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS079860

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel